CAIM
RXRX icon

Catherine Avery Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Catherine Avery Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70
Closed -$473 – 181
2024
Q4 		$473 Buy
+70
New +$471 ﹤0.01% 165

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Catherine Avery Investment Management's RXRX Position: Q1 2025 in Review

Catherine Avery Investment Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 70 shares — an estimated $473 sold.

Catherine Avery Investment Management first reported a position in RXRX in Q4 2024 and held it in 1 quarter. The position peaked at $473 in Q4 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Catherine Avery Investment Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Catherine Avery Investment Management sold 70 Recursion Pharmaceuticals shares in Q1 2025, an estimated $473.
  • Catherine Avery Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Catherine Avery Investment Management's Recursion Pharmaceuticals position peaked at $473 in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Catherine Avery Investment Management's 13F filing for Q1 2025, filed 5 Jan 2026.